• Eugenia Villanueva, Marcelina Carretero, María A Aguirre, Agustina Negro, César A Belziti, María L Posadas-Martínez, Elsa M Nucifora, Sergio Baratta, Juan P Costabel, Claudio Higa, Carlos Rivas, Adrián Fernández, Alejandro Quiroga, Carlos A Dumont, Verónica I Volberg, Gisela M Streitenberg, and Diego Perez de Arenaza.
• Servicio de Cardiología, Hospital Italiano de Buenos Aires, Argentina. E-mail: eugenia.villanueva@hospitalitaliano.org.ar.
• Medicina (B Aires). 2022 Jan 1; 82 (2): 275-288.

AbstractThis clinical practice guideline for treating transthyretin amyloid (ATTR) cardiomyopathy is based on the best available evidence of clinical effectiveness. The PICO format was used to generate a list of questions focused on the effectiveness and safety of the specific treatment of patients with ATTR cardiomyopathy. The search was conducted in PubMed, Cochrane and Epistemokus, between July-August 2020, and selected articles between 2000-2020, in English and Spanish. The level of evidence and recommendations were analyzed and classified by the GRADE system. The following drugs were included in the analysis: tafamidis, diflunisal, inotersen, patisiran y doxycycline and ursodeoxycholic acid. The expert panel had an agreement that tafamidis 80mg/daily is the only available drug with moderate evidence and weak recommendation for the reduction of total mortality, cardiovascular morbidity, heart failure hospitalization and progression of the disease in patients with ATTR cardiomyopathy and NYHA class = 3. In contrast, tafamidis 20 mg/daily had low-quality evidence in this group of patients. The expert panel did not recommend inotersen, patisiran and diflunisal in patients with ATTR cardiomyopathy due to the lack of supporting evidence, local drug availability, and the potential risk of toxicity. When patients did not have access to tafamidis, the expert panel stated a weak recommendation to use doxycycline and ursodeoxycholic acid in patients with ATTR cardiomyopathy.

19 keywords...

hide…